Advancing Multiple Myeloma Care: Insights From ASH 2024 and Beyond

January 17, 2025

Saad Z. Usmani, MD, MBA, FACP

Opinion

Video

Saad Z. Usmani, MD, MBA, FACP, discusses noteworthy data presented at ASH 2024, including the IFM2017-03 trial, and shares his excitement for ongoing research efforts in multiple myeloma, emphasizing key areas where further investigation is needed to improve patient outcomes and refine treatment strategies.

EP: 1.Early Intervention in High-Risk Smoldering Myeloma: Results From the AQUILA Study at ASH 2024

EP: 2.Exploring the Frontline Potential of Teclistamab: Insights From MajesTEC-5 at ASH 2024

EP: 3.MRD Outcomes From CEPHEUS at ASH 2024

EP: 4.Transplant-Ineligible Myeloma and MRD Integration: Current Definitions and Future Directions

EP: 5.Anitocabtagene Autoleucel in Focus: Insights From the iMMagine-1 Trial at ASH 2024

Now Viewing

EP: 6.Advancing Multiple Myeloma Care: Insights From ASH 2024 and Beyond

Video content above is prompted by the following:

Please discuss any other data in multiple myeloma released at ASH 2024 that you find noteworthy to share with colleagues.
Outside of ASH 2024, what ongoing research efforts are you most excited for in the treatment of multiple myeloma, and what are some key areas where you think further research is needed to continue improving patient outcomes?

Related Content

ICYMI: Highlights From AMCP Nexus 2024

December 26th 2024

Article

Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.

ICYMI: Highlights From ASCO 2024

December 21st 2024

Article

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

ICYMI: Highlights From SLEEP 2024

December 18th 2024

Article

Check out our top 5 most-viewed pieces of coverage from the 2024 SLEEP meeting.

ICYMI: Highlights From ACTRIMS 2024

December 12th 2024

Article

Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS).